Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Neutral

Analyst Rating

Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Strong Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Eiger BioPharmaceuticals, Inc. (EIGR)

Biological Products, (no Disgnostic Substances)

https://www.eigerbio.com

Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

2155 PARK BOULEVARD
PALO ALTO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/30/2014

Market Cap

2,552,120

Shares Outstanding

1,480,000

Weighted SO

1,479,489

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

SPRO --.--%

BOLT --.--%

CHRS --.--%

GRCL --.--%

NLTX --.--%

CING --.--%

LYRA --.--%

FNCH --.--%

APLT --.--%

Beta

1.8450

Last Div

0.0000

Range

1.1-43.35

Chg

-0.1750

Avg Vol

113731

Mkt Cap

2552120

Exch

NASDAQ

Country

US

Phone

650 272 6138

DCF Diff

1.6936

DCF

-0.3635

Div Yield

0.0000

P/S

0.1618

EV Multiple

-0.2645

P/FV

-0.1762

Div Yield %

0.0000

P/E

-0.0340

PEG

-0.0048

Payout

0.0000

Current Ratio

0.7101

Quick Ratio

0.5090

Cash Ratio

0.4774

DSO

38.9228

DIO

881.8944

Op Cycle

920.8173

DPO

1198.7189

CCC

-277.9017

Gross Margin

0.9592

Op Margin

-4.5512

Pretax Margin

-4.7522

Net Margin

-4.7526

Eff Tax Rate

0.0026

ROA

-1.9307

ROE

-8.6984

ROCE

4.9651

NI/EBT

1.0001

EBT/EBIT

1.0442

EBIT/Rev

-4.5512

Debt Ratio

1.0612

D/E

-2.8498

LT Debt/Cap

0.0000

Total Debt/Cap

1.5406

Int Coverage

-27.1711

CF/Debt

-1.8093

Equity Multi

-2.6854

Rec Turnover

9.3775

Pay Turnover

0.3045

Inv Turnover

0.4139

FA Turnover

25.1563

Asset Turnover

0.4062

OCF/Share

-50.4797

FCF/Share

-50.6381

Cash/Share

17.2265

OCF/Sales

-4.7263

FCF/OCF

1.0031

CF Coverage

-1.8093

ST Coverage

-1.8093

CapEx Coverage

-318.5812

Div&CapEx Cov

-318.5812

P/BV

-0.1762

P/B

-0.1762

P/S

0.1618

P/E

-0.0340

P/FCF

-0.0341

P/OCF

-0.0342

P/CF

-0.0342

PEG

-0.0048

P/S

0.1618

EV Multiple

-0.2645

P/FV

-0.1762

DPS

0.0000

Latest Headlines (EST)

No Headlines Found

Revenue Product Segmentation